Brain metastases occur in 20% to 32% of patients diagnosed with NSCLC [2, 3], most frequently in patients with adenocarcinomas and tumors harboring EGFR mutations or ALK rearrangements with an incidence of up to 72% [4–6]. The gene discussed is EGFR; the disease is adenocarcinoma.